ENLV vs. ORGS, CLSD, CNTB, PRPH, LFVN, ASRT, ORMP, YS, RLMD, and ETON
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Orgenesis (ORGS), Clearside Biomedical (CLSD), Connect Biopharma (CNTB), ProPhase Labs (PRPH), LifeVantage (LFVN), Assertio (ASRT), Oramed Pharmaceuticals (ORMP), YS Biopharma (YS), Relmada Therapeutics (RLMD), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
Enlivex Therapeutics has a net margin of 0.00% compared to Enlivex Therapeutics' net margin of -1,343.97%. Orgenesis' return on equity of -71.00% beat Enlivex Therapeutics' return on equity.
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 5.7% of Orgenesis shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Orgenesis has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
Enlivex Therapeutics received 48 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 77.78% of users gave Enlivex Therapeutics an outperform vote.
Enlivex Therapeutics has a consensus price target of $7.00, indicating a potential upside of 414.67%. Given Orgenesis' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Orgenesis.
Enlivex Therapeutics has lower revenue, but higher earnings than Orgenesis.
In the previous week, Orgenesis had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Orgenesis and 4 mentions for Enlivex Therapeutics. Orgenesis' average media sentiment score of 0.99 beat Enlivex Therapeutics' score of 0.26 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.
Summary
Enlivex Therapeutics beats Orgenesis on 10 of the 14 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
